Ad Hoc Announcements
Date Title
Apr 09, 2013 Ad hoc announcement: Agennix AG Announces Extraordinary General Meeting
Mar 26, 2013 Agennix AG Reports Notice of Loss Pursuant to § 92 par. 1 AktG
Aug 06, 2012 Agennix Reports Results of FORTIS-M Phase III Trial with Talactoferrin Alfa in Non-small Cell Lung Cancer
Feb 02, 2012 Agennix AG Halts Phase II/III OASIS Trial in Severe Sepsis
Dec 07, 2011 Ad hoc announcement: Agennix AG Successfully Completes Rights Offering in the Amount of Approximately € 27.5 Million
Nov 16, 2011 Ad hoc announcement: Agennix AG Announces Planned Rights Offering and Capital Increase
Nov 04, 2010 dievini Hopp BioTech Holding and Related Persons and Entities Granted Exemption from Mandatory Tender Offer for Agennix AG
Oct 01, 2010 Agennix AG Raises Approximately € 76 Million in Net Proceeds
Sep 15, 2010 Agennix AG Sets Subscription Price at € 3.81 per Share for Capital Increase and Subscription Period Planned to Begin on September 17, 2010
Jul 23, 2010 Agennix AG Secures € 15 Million Loan
Mar 21, 2010 Agennix AG Raises EUR 9.8 Million (~$13 Million) in Private Placement with Existing Shareholders
Dec 01, 2009 Agennix AG Announces Positive Results with Talactoferrin in Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Severe Sepsis
Nov 05, 2009 Merger of GPC Biotech AG into Agennix AG Closes